Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder

Archives of General Psychiatry

Volumn 63, Issue 7, 2006, Pages 741-747

  Cannon, Dara M ^a   Carson, Richard E ^d   Nugent, Allison C ^a   Eckelman, William C ^e   Kiesewetter, Dale O ^b   Williams, Joan ^c   Rollis, Denise ^c   Drevets, Michele ^a   Gandhi, Shilpa ^a   Solorio, Gerardo ^a   Drevets, Wayne C ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Molecular Tracer LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; FLUOXETINE; MUSCARINIC M2 RECEPTOR; PSYCHOTROPIC AGENT; RADIOLIGAND;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CINGULATE GYRUS; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; HAMILTON ANXIETY SCALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; POSITRON EMISSION TOMOGRAPHY; RECEPTOR BINDING;

ACETYLCHOLINE; ADULT; AMBULATORY CARE; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUORODEOXYGLUCOSE F18; GYRUS CINGULI; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M2; SYNAPSES; THIAZOLES; TISSUE DISTRIBUTION;

EID: 33745712727     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.7.741     Document Type: Article

References (42)

1. WHO. Burden of mental and behavioural disorders. http://www.who.int/whr/ 2001 /en/whr01_ch2_en.pdf. Accessed September 16, 2005.
2. Dilsaver SC. Pathophysiology of "cholinoceptor supersensitivity" in affective disorders. Biol Psychiatry. 1986;21:813-829.
3. McGaugh JL. The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci. 2004;27:1-28.
4. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception, II: implications for major psychiatric disorders. Biol Psychiatry. 2003;54:515-528.
5. Benson BE, Carson RE, Kiesewetter DO, Herscovitch P, Eckelman WC, Post RM, Ketter TA. A potential cholinergic mechanism of procaine's limbic activation. Neuropsychopharmacology. 2004;29:1239-1250.
6. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S, Kwon JM, Wu W, Dick DM, Rice J, Jones K, Nurnberger JI Jr, Tischfield J, Porjesz B, Edenberg HJ, Hesselbrock V, Crowe R, Schuckit M, Begleiter H, Reich T, Goate AM, Bierut LJ. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet. 2004;13:1903-1911.
7. Comings DE, Wu S, Rostamkhani M, McGue M, Iacono WG, MacMurray JP. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet. 2002;114:527-529.
8. Ketter TA, Andreason PJ, George MS, Lee C, Gill DS, Parekh PI, Willis MW, Herscovitch P, Post RM. Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Arch Gen Psychiatry. 1996;53:59-69.
9. Jagoda EM, Kiesewetter DO, Shimoji K, Ravasi L, Yamada M, Gomeza J, Wess J, Eckelman WC. Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology. 2003;44:653-661.
10. Carson RE, Kiesewetter DO, Jagoda E, Der MG, Herscovitch P, Eckelman WC. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab. 1998;18:1130-1142.
11. Berg J, Tymoczko J, DStryer L. Seven-transmembrane-helix receptors change conformation in response to ligand binding and activate g-proteins. In: Biochemistry. 5th ed. New York, NY: WH Freeman; 2002:398-403.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
14. Young RC, Briggs JT, Zieger VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429-435.
15. Murphy FC, Sahakian BJ, Rubinsztein JS, Michael A, Rogers RD, Robbins TW, Paykel ES. Emotional bias and inhibitory control processes in mania and depression. Psychol Med. 1999;29:1307-1321.
16. Kiesewetter DO, Vuong BK, Channing MA. The automated radiosynthesis of [18F]FP-TZTP. Nucl Med Biol. 2003;30:73-77.
17. Ma Y, Kiesewetter DO, Jagoda EM, Huang BX, Eckelman WC. Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-me thylpyridine, produced by human and rat hepatocytes. J Chromatogr B Biomed Sci Appl. 2002;766:319-329.
18. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 1993;17:536-546.
19. Jenkinson M, Bannister P, Brady J, Smith S. Improved optimisation for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825-841.
20. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12:571-583.
21. Pham DL, Prince JL. Adaptive fuzzy segmentation of magnetic resonance images. IEEE Trans Med Imaging. 1999;18:737-752.
22. Statistical Parametric Mapping. SPM Web site. http://www.fil.ion.ucl.ac. uk /spm/. Accessed September 16, 2005.
23. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71:431-447.
24. Mash DC, White WF, Mesulam MM. Distribution of muscarinic receptor sub-types within architectonic subregions of the primate cerebral cortex. J Comp Neurol. 1988;278:265-274.
25. Smiley JF, Levey AI, Mesulam MM. Infracortical interstitial cells concurrently expressing m2-muscarinic receptors, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate-diaphorase in the human and monkey cerebral cortex. Neuroscience. 1998;84:755-769.
26. Poline JB, Worsley KJ, Holmes AP, Frackowiak RS, Friston KJ. Estimating smoothness in statistical parametric maps: variability of P values. J Comput Assist Tomogr. 1995;19:788-796.
27. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburg J, Burns CT. The Inventory for Depressive Symptomatology (IDS): preliminary finding. Psychiatry Res. 1986;18:65-87.
28. Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull. 2005;65:397-403.
29. Burstein ES, Spalding TA, Brann MR. Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol. 1997;51:312-319.
30. De Lean A, Stadel J, Lefkowitz R. A ternary complex model explains the agonistspecific binding properties of the adenylate cyclase-coupled-adrenergic receptor. J Biol Chem. 1980;255:7108-7117.
31. Ross E. Pharmacodynamics. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Professional; 1996.
32. Drevets WC, Price J, Simpson J, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824-827.
33. Janowsky D, Overstreet D. The role of acetylcholine mechanisms in affective disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology, The Fourth Generation of Progress. New York, NY: Lippincott Williams and Wilkins, Raven Press; 2000.
34. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry. 2003;8:673-679.
35. Drevets W, Todd R. Depression, mania and related disorders. In: Rubin E, Zorumski C, eds. Adult Psychiatry. 2nd ed. Oxford, England: Blackwell Publishing, Ltd; 2005.
36. Sarter M, Nelson CL, Bruno JP. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull. 2005;31:117-138.
37. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol. 1997;48:649-684.
38. McGaughy J, Everitt BJ, Robbins TW, Sarter M. The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins. Behav Brain Res. 2000;115:251-263.
39. Clark L, Iversen SD, Goodwin GM. Sustained attention deficit in bipolar disorder. Br J Psychiatry. 2002;180:313-319.
40. Fritze J, Beckmann H. The cholinergic agonist RS 86: a pharmacopsychological study. Neuropsychobiology. 1988;19:35-39.
41. Salinas JA, Introini-Collison IB, Dalmaz C, McGaugh JL. Posttraining intraamygdala infusions of oxotremorine and propranolol modulate storage of memory for reductions in reward magnitude. Neurobiol Learn Mem. 1997;68:51-59.
42. Vogt BA, Sikes RW. The medial pain system, cingulate cortex, and parallel processing of nociceptive information. Prog Brain Res. 2000;122:223-235.